Clinical experience with endothelin receptor antagonists in chronic heart failure

Heart Failure Reviews

Volumn 6, Issue 4, 2001, Pages 317-323

  Seed, Alison ^a   Love, Michael P ^a   Mcmurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chronic heart failure; Endothelin; Receptor antagonist; Therapeutics

Indexed keywords

AMINOTRANSFERASE; ATRASENTAN; BMS 193884; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NEUROHORMONE; PLACEBO; SITAXSENTAN; TEZOSENTAN; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE CLASSIFICATION; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELECTIVITY; EVALUATION; HEART FAILURE; HEART HEMODYNAMICS; HEMATOCRIT; HEMODYNAMIC PARAMETERS; HUMAN; LONG TERM CARE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SCHOOL CHILD; SHORT COURSE THERAPY; TREATMENT OUTCOME;

CHRONIC DISEASE; CLINICAL TRIALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MIDDLE AGED; RECEPTORS, ENDOTHELIN;

EID: 0034903761     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011408425878     Document Type: Review

References (28)

1. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
2. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure
3. Endothelin receptor antagonism in patients with chronic heart failure
4. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
5. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators
6. Improved haemodynamics with the ET A selective receptor antagonist BMS-193884 in patients with heart failure
7. Safety and efficacy of an orally active selective endothelin-A receptor antagonist in moderate-severe human chronic heart failure
8. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
9. Tezosentan (the first i.v. endothelin receptor A/B antagonist) reduces peripheral resistance and increases myocardial contractility despite reducing left ventricular filling (wedge) pressure in patients with congestive heart failure
10. A new strategy for a clinical development program in acute and decompensated heart failure: The randomized intravenous TeZosentan (RITZ) trials
11. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
12. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
13. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
14. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins
15. Role of endothelin in the increased vascular tone of patients with essential hypertension
16. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
17. Clinical and haemodynamic effects of chronic selective ETA receptor blockade in congestive heart failure (HEAT, heart failure ETA receptor blockade trial)
18. Chronic selective ETA receptor blockade in congestive heart failure. The heat trial (heart failure ETA receptor blockade trial)
19. Neurohumoral and haemodynamic effects of the selective endothelin antagonist LU 135252 in advanced chronic heart failure after three weeks
20. Neurohumoral and hemodynamic effects of the selective endothelin antagonist LU 135252 in advanced heart failure
21. Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production
22. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats
23. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure
24. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism
25. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
26. Endothelin clearance in patients with chronic heart failure: Implications for anti endothelin therapy
27. Multicentre, double blind, placebo controlled study of long term endothelin blockade with bosentan in chronic heart failure: Results of the Reach trial
28. Multicentre, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial